1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
AssigneesIncyte Corporation, Incyte Holdings Corporation
InventorsAndrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu
Life of this patent
Estimating the term…
Abstract
The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
Claims4
A compound, which is 4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide, wherein one or more hydrogen atoms are replaced by deuterium;
- or a pharmaceutically acceptable salt thereof.
A compound, which is 4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide, wherein one or more hydrogen atoms are replaced by deuterium.
Dependencies are inferred from the claim text.